An Update on Site Relationship Management (SRM) Initiatives
Beth Harper, MBA, president, Clinical Performance Partners, offers Site Relationship Management initiative insights from the past year.
Yesterday, Beth Harper MBA, president, Clinical Performance Partners presented on the panel for the Clinical Research/Clinical Supplies track “Site Relationship Management (SRM) Initiatives for Improving Site Performance: One Year Later.” This session was an update from last year and presented specific goals, plans and initiatives that pharma and CROs were implementing to address SRM.
Applied Clinical Trials spoke to Beth Harper about this year’s session.
Q: What do you feel has changed the most in regard to site relationship management in the past year?
A: There is interest and visibility and dialogue about the topic. Actually engaging the site in the partnership is now part of the normal conversation that has elevated significantly. It’s a commonplace question and the site aspect is no longer an afterthought.
Q: Last year, you presented on this topic. It's exciting to see material that is updated regularly. What did you find to present as an update over last year?
A: The theme for this year would be, “The best laid plans of mice and men.” With the economy, mergers, and the resource constraints brought on by that, many of the SRM programs didn’t progress as much as we thought. So the actual data to present was not as robust.
The good news is that the spirit is still there. We are continuing the conversation and people are still excited about SRM initiatives.
Q: In your view, what successes are we seeing at the site level, and for sponsors?
A: In some cases we are starting to see pay-offs in terms of faster recruitment but the jury is still out, overall. However, Quintiles’ offered metrics that it has seen a 124% relative increase in recruitment rate with their Partner Sites over the last three years.
Another success is that the dialogue is opening up, there is listening to the needs of the stakeholders but whether or not it’s accelerating we aren’t sure because there is nothing measurable.
But everyone is coming to the table to discuss. And we know if we don’t set our sites up for success, then we won’t have the product development weneed.
For more articles about Site Relationship Management:
Good Site and Sponsor Relationships Pay Off
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
